drugset / Trial / NCT07163650
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
Phase 4
Recruiting
60 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.
Timeline
- Start
- 2025-09-16
- Primary completion
- 2026-11-30
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efsubaglutide Alfa | Protein / enzyme biologic | 9 mg | Subcutaneous |